BidaskClub upgraded shares of Epizyme, Inc. (NASDAQ:EPZM) from a strong sell rating to a sell rating in a research note issued to investors on Saturday morning.
Several other analysts have also recently issued reports on EPZM. Cann reaffirmed an outperform rating and issued a $26.00 price target on shares of Epizyme in a report on Wednesday, April 12th. Oppenheimer Holdings, Inc. started coverage on shares of Epizyme in a research note on Thursday, April 13th. They set an outperform rating and a $26.00 target price for the company. CIBC reiterated an outperform rating on shares of Epizyme in a research note on Thursday, April 13th. Royal Bank Of Canada reiterated an outperform rating and set a $20.00 target price (up previously from $19.00) on shares of Epizyme in a research note on Wednesday, May 10th. Finally, Zacks Investment Research upgraded shares of Epizyme from a hold rating to a buy rating and set a $18.00 target price for the company in a research note on Tuesday, May 16th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eleven have issued a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus target price of $23.75.
Epizyme (NASDAQ EPZM) opened at 13.60 on Friday. Epizyme has a 52-week low of $7.02 and a 52-week high of $18.50. The company has a 50 day moving average of $13.86 and a 200-day moving average of $14.31. The stock’s market capitalization is $793.67 million.
Epizyme (NASDAQ:EPZM) last posted its quarterly earnings results on Friday, August 4th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.08. The firm had revenue of $10 million for the quarter, compared to analysts’ expectations of $3.95 million. Epizyme had a negative net margin of 1,376.33% and a negative return on equity of 58.97%. The firm’s quarterly revenue was up 2027.7% on a year-over-year basis. During the same period in the prior year, the company posted ($0.49) earnings per share. Equities research analysts anticipate that Epizyme will post ($2.42) EPS for the current year.
TRADEMARK VIOLATION WARNING: This report was first published by Markets Daily and is owned by of Markets Daily. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://www.themarketsdaily.com/2017/08/08/epizyme-inc-nasdaqepzm-raised-to-sell-at-bidaskclub.html.
In related news, insider Robert A. Copeland sold 2,500 shares of the company’s stock in a transaction dated Tuesday, June 6th. The shares were sold at an average price of $13.45, for a total value of $33,625.00. Following the completion of the sale, the insider now owns 34,038 shares of the company’s stock, valued at $457,811.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Peter Tai-Ching Ho sold 15,000 shares of the company’s stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $13.44, for a total transaction of $201,600.00. Following the completion of the sale, the insider now directly owns 22,228 shares of the company’s stock, valued at approximately $298,744.32. The disclosure for this sale can be found here. Insiders have sold 50,524 shares of company stock valued at $746,797 in the last 90 days. Insiders own 25.20% of the company’s stock.
A number of large investors have recently bought and sold shares of the company. Legal & General Group Plc increased its stake in Epizyme by 8.9% in the first quarter. Legal & General Group Plc now owns 9,684 shares of the biopharmaceutical company’s stock valued at $165,000 after buying an additional 795 shares during the last quarter. UBS Asset Management Americas Inc. bought a new stake in Epizyme during the first quarter valued at $175,000. BB&T Securities LLC bought a new stake in Epizyme during the second quarter valued at $181,000. Trexquant Investment LP bought a new stake in Epizyme during the second quarter valued at $184,000. Finally, SG Americas Securities LLC increased its stake in Epizyme by 83.3% in the second quarter. SG Americas Securities LLC now owns 13,364 shares of the biopharmaceutical company’s stock valued at $202,000 after buying an additional 6,072 shares during the last quarter. 81.30% of the stock is owned by institutional investors and hedge funds.
Epizyme Company Profile
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.